EUVIMEDEUVIMED entdecken
Multizentrische Studie

Adverse Events in Testicular Cancer Survivors Using EORTC QLQ‐TC26: A Multi‐Institutional, Cross‐Sectional Study in Japan

Takuro Goto iD, Shinichi Yamashita iD, Kenichi Kakimoto, Motohide Uemura, Takeshi Kishida iD, Takashi Kawahara iD, Terukazu Nakamura, Takayuki Goto iD, Takahiro Osawa iD, Kazuo Nishimura iD, Norio Nonomura, Hiroyuki Nishiyama und 7 weitere

International Journal of Urology · 2026

DOI: 10.1111/iju.70261 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Urology, 2026. Verfasst von Takuro Goto und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Cancer Survivors, Neoplasms, Germ Cell and Embryonal, Quality of Life. Die Arbeit nennt 23 Literaturangaben. Gefördert von: JSPS KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate adverse events in testicular cancer survivors using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire‐Testicular Cancer 26 (EORTC QLQ‐TC26).

Methods

Testicular cancer survivors at eight high‐volume institutions in Japan were surveyed regarding age, International Germ Cell Consensus Classification, number of chemotherapy cycles, paclitaxel use, follow‐up period after treatment, and adverse events scores of EORTC QLQ‐TC26. Adverse events scores were assessed by the number of chemotherapy cycles and the follow‐up period.

Results

A total of 551 testicular cancer survivors responded to the adverse events questionnaires of EORTC QLQ‐TC26. Median age at response was 43 years and median follow‐up was 61 months. Chemotherapy was administered to 393 (71%) survivors, and paclitaxel was used in 91 (17%) survivors. Testicular cancer survivors who received three or more cycles of chemotherapy showed significantly worse adverse events scores than those without chemotherapy. Scores for tingling or numbness in the fingers or toes, pale/cold fingers or toes, and problems with hearing were affected by chemotherapy. Tingling or numbness tended to improve over time, whereas problems with hearing showed no evidence of improvement. In addition, scores for tingling or numbness were worse when paclitaxel was used.

Conclusions

Testicular cancer survivors suffered from adverse events with three or more cycles of chemotherapy, and problems with hearing did not improve after treatment. We should provide testicular cancer survivors with adequate information about long‐lasting adverse events, particularly problems with hearing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsCancer SurvivorsNeoplasms, Germ Cell and EmbryonalQuality of LifeTesticular NeoplasmsAdolescentAdultAgedHumansMaleMiddle AgedYoung AdultCross-Sectional StudiesFollow-Up StudiesJapanPaclitaxelSurveys and Questionnaires

Stichwörter der Autor:innen

EORTC QLQ‐TC26adverse eventcross‐sectional studysurvivortesticular cancer

Substanzen

Paclitaxel

Autor:innen und Institutionen

  • Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Department of Urology, Osaka International Cancer Institute, Osaka, Japan.
  • Department of Urology, The University of Osaka Graduate School of Medicine, Suita, Japan.
  • Department of Urology, Kanagawa Cancer Center, Yokohama, Japan.
  • Department of Urology, University of Tsukuba, Tsukuba, Japan.
  • Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

ORCID-Profile: Takuro Goto, Shinichi Yamashita, Takeshi Kishida, Takashi Kawahara, Takayuki Goto, Takahiro Osawa, Kazuo Nishimura, Takumi Shiraishi, Osamu Ukimura

Förderung

  • JSPS KAKENHI

Zitieren

APA

Goto, T., Yamashita, S., Kakimoto, K., Uemura, M., Kishida, T., Kawahara, T., Nakamura, T., Goto, T., Osawa, T., Nishimura, K., Nonomura, N., Nishiyama, H., Shiraishi, T., Ukimura, O., Ogawa, O., Shinohara, N., Suzukamo, Y., Ito, A., & Arai, Y. (2026). Adverse Events in Testicular Cancer Survivors Using EORTC QLQ‐TC26: A Multi‐Institutional, Cross‐Sectional Study in Japan. International Journal of Urology. https://doi.org/10.1111/iju.70261

Vancouver

Goto T, Yamashita S, Kakimoto K, Uemura M, Kishida T, Kawahara T, et al. Adverse Events in Testicular Cancer Survivors Using EORTC QLQ‐TC26: A Multi‐Institutional, Cross‐Sectional Study in Japan. International Journal of Urology. 2026. doi:10.1111/iju.70261

BibTeX
@article{Goto2026,
  author = {Goto, Takuro and Yamashita, Shinichi and Kakimoto, Kenichi and Uemura, Motohide and Kishida, Takeshi and Kawahara, Takashi and Nakamura, Terukazu and Goto, Takayuki and Osawa, Takahiro and Nishimura, Kazuo and Nonomura, Norio and Nishiyama, Hiroyuki and Shiraishi, Takumi and Ukimura, Osamu and Ogawa, Osamu and Shinohara, Nobuo and Suzukamo, Yoshimi and Ito, Akihiro and Arai, Yoichi},
  title = {Adverse Events in Testicular Cancer Survivors Using EORTC QLQ‐TC26: A Multi‐Institutional, Cross‐Sectional Study in Japan},
  journal = {International Journal of Urology},
  year = {2026},
  doi = {10.1111/iju.70261}
}
Kostenlos starten →